Elisa Brietzke

Prof. Elisa Brietzke


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
ZPZihang Pan
Zihang Pan
CPCaroline Park
Caroline Park
EBElisa Brietzke
Elisa Brietzke
HZHannah Zuckerman
Hannah Zuckerman
CRCarola Rong
Carola Rong
RMRoger McIntyre
Roger McIntyre
Cognitive dysfunction is a symptomatic domain identified across many mental disorders. Cognitive deficits in individuals with major depressive disorder (MDD) contribute significantly to occupational and functional disability. Notably, cognitive subdomains such as learning and memory, executive functioning, processing speed, and attention and concentration are significantly impaired during, and between, episodes in individuals with MDD. Most antidepressants have not been developed and/or evaluated for their ability to directly and independently ameliorate cognitive deficits. Multiple interacting neurobiological mechanisms (eg, neuroinflammation) are implicated as subserving cognitive deficits in MDD. A testable hypothesis, with preliminary support, posits that improving performance across cognitive domains in individuals with MDD may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes, independent of effects on core mood symptoms. Herein we aim to (1) provide a rationale for prioritizing cognitive deficits as a therapeutic target, (2) briefly discuss the neurobiological substrates subserving cognitive dysfunction, and (3) provide an update on current and future treatment avenues.

1 May 2014 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
LRLucas Bortolotto Rizzo
Lucas Bortolotto Rizzo
LCLeonardo Gazzi Costa
Leonardo Gazzi Costa
RMRodrigo B. Mansur
Rodrigo B. Mansur
WSWalter Swardfager
Walter Swardfager
SBSíntia Iole Belangero
Síntia Iole Belangero
EBElisa Brietzke
Elisa Brietzke

1 February 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
PMPawan Kumar Maurya
Pawan Kumar Maurya
CNCristiano Noto
Cristiano Noto
LRLucas B. Rizzo
Lucas B. Rizzo
ARAdiel C. Rios
Adiel C. Rios
SNSandra O.V. Nunes
Sandra O.V. Nunes
EBElisa Brietzke
Elisa Brietzke

19 October 2017 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
LBLineth H.U. Bustamante
Lineth H.U. Bustamante
RCRaphael O. Cerqueira
Raphael O. Cerqueira
ELEmilie Leclerc
Emilie Leclerc
EBElisa Brietzke
Elisa Brietzke
Key words: PTSD; migration; stress; trauma; mental health services

9 October 2015 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
SSSumit Sethi
Sumit Sethi
EBElisa Brietzke
Elisa Brietzke
One of the major concerns of modern society is to identify putative biomarkers that serve as a valuable early diagnostic tool to identify a subset of patients with increased risk to develop neuropsychiatric disorders. Biomarker identification in neuropsychiatric disorders is proposed to offer a number of important benefits to patient well-being, including prediction of forthcoming disease, diagnostic precision, and a level of disease description that would guide treatment choice. Nowadays, the metabolomics approach has unlocked new possibilities in diagnostics of devastating disorders like neuropsychiatric disorders. Metabolomics-based technologies have the potential to map early biochemical changes in disease and hence provide an opportunity to develop predictive biomarkers that can be used as indicators of pathological abnormalities prior to development of clinical symptoms of neuropsychiatric disorders. This review highlights different -omics strategies for biomarker discovery in neuropsychiatric disorders. We also highlight initial outcomes from metabolomics studies in psychiatric disorders such as schizophrenia, bipolar disorder, and addictive disorders. This review will also present issues and challenges regarding the implementation of the metabolomics approach as a routine diagnostic tool in the clinical laboratory in context with neuropsychiatric disorders.

CRCarola Rong
Carola Rong
CPCaroline Park
Caroline Park
JRJoshua Rosenblat
Joshua Rosenblat
MSMehala Subramaniapillai
Mehala Subramaniapillai
HZHannah Zuckerman
Hannah Zuckerman
RMRoger McIntyre
Roger McIntyre
Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to identify the pretreatment predictors of response to ketamine in TRD as part of MDD and BD. Method: Electronic search engines PubMed/MEDLINE, ClinicalTrials.gov, and Scopus were searched for relevant articles from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. Results: Multiple baseline pretreatment predictors of response were identified, including clinical (i.e., Body Mass Index (BMI), history of suicide, family history of alcohol use disorder), peripheral biochemistry (i.e., adiponectin levels, vitamin B12 levels), polysomnography (abnormalities in delta sleep ratio), neurochemistry (i.e., glutamine/glutamate ratio), neuroimaging (i.e., anterior cingulate cortex activity), genetic variation (i.e., Val66Met BDNF allele), and cognitive functioning (i.e., processing speed). High BMI and a positive family history of alcohol use disorder were the most replicated predictors. Conclusions: A pheno-biotype of depression more, or less likely, to benefit with ketamine treatment is far from complete. Notwithstanding, metabolic-inflammatory alterations are emerging as possible pretreatment response predictors of depressive symptom improvement, most notably being cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment predictive information.